{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:15Z","timestamp":1792788315137,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Zurich","id":[{"id":"https:\/\/ror.org\/02crff812","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical trial registries document trial design, funding, and results reporting, but heterogeneous and unstructured entries limit cross-trial comparison. Consequently, it is unclear how neurology and psychiatry drug trials are designed and reported in practice, hampering comparison of studies, understanding of the available evidence, and planning of future trials. The aim of this study was to quantify trial design features, results reporting practices, and research focus in neurology and psychiatry drug trials using harmonized registry data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a registry-based observational study of interventional neurology and psychiatry drug trials registered on ClinicalTrials.gov between 2000 and 2023. Using natural language processing (NLP)\u00a0with manual validation, we extracted and harmonized trial information on phase, randomization, masking, sample size, funding source, results reporting, and target diseases and drugs. We also performed content-based clustering and visualization to explore patterns across trials by drug and disease category. We analyzed temporal trends and differences across trial characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 18,609 trials. Most were early phase, single-center, and small, typically enrolling 11\u201350 participants; 60% were completed. Industry funded 36% of trials, with a declining share over time and a corresponding increase in university sponsorship. Ten percent of trials were non-randomized and 38% were open label. Among trials completed after 2007, 50% reported results, with a mean delay of 12\u00a0months. The most frequently studied conditions were pain (10%), schizophrenia (8%), depression (8%), and Alzheimer\u2019s disease (7%). Drug testing was widely distributed, with atypical antipsychotics, levodopa, and ketamine each accounting for 1\u20132% of trials. Content-based clustering identified disease-specific groupings of trials. Harmonized data are available through an interactive dashboard.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Registered neurology and psychiatry drug trials show persistent limitations in design and results reporting despite two decades of registry requirements. Registry-based analyses using computational harmonization can support empirical evaluation of trial practices and inform future trial design and reporting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09909-8","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:34:29Z","timestamp":1785216869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design, reporting, and research focus of neurology and psychiatry drug trials (2020\u20132023): a registry-based meta-epidemiological study using ClinicalTrials.gov and NLP"],"prefix":"10.1186","volume":"27","author":[{"given":"Simona Emilova","family":"Doneva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Sick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilia R.","family":"Ellendorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars G.","family":"Hemkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerold","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Victor","family":"Ineichen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"5","key":"9909_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"VL Feigin","year":"1990","unstructured":"Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 1990;18(5):459\u201380.","journal-title":"Lancet Neurol"},{"issue":"6","key":"9909_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002667","volume":"22","author":"BV Ineichen","year":"2024","unstructured":"Ineichen BV, Furrer E, Gr\u00fcninger SL, Z\u00fcrrer WE, Macleod MR. Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications. PLoS Biol. 2024;22(6):e3002667. https:\/\/doi.org\/10.1371\/journal.pbio.3002667.","journal-title":"PLoS Biol"},{"key":"9909_CR3","doi-asserted-by":"crossref","unstructured":"Tse T, Fain KM, Zarin DA. How to avoid common problems when using ClinicalTrials. gov in research: 10 issues to consider. Bmj. 2018;361:k1452.","DOI":"10.1136\/bmj.k1452"},{"key":"9909_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-019-3592-0","volume":"20","author":"M Pillamarapu","year":"2019","unstructured":"Pillamarapu M, Mohan A, Saberwal G. An analysis of deficiencies in the data of interventional drug trials registered with Clinical Trials Registry-India. Trials. 2019;20:1\u201317.","journal-title":"Trials"},{"issue":"1","key":"9909_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-023-02869-7","volume":"11","author":"X Shi","year":"2024","unstructured":"Shi X, Du J. Constructing a finer-grained representation of clinical trial results from ClinicalTrials. gov. Sci Data. 2024;11(1):41.","journal-title":"Sci Data"},{"issue":"3","key":"9909_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033677","volume":"7","author":"A Tasneem","year":"2012","unstructured":"Tasneem A, Aberle L, Ananth H, Chakraborty S, Chiswell K, McCourt BJ, et al. The database for aggregate analysis of ClinicalTrials. gov (AACT) and subsequent regrouping by clinical specialty. PLoS ONE. 2012;7(3):e33677.","journal-title":"PLoS ONE"},{"key":"9909_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1228148","volume":"14","author":"ED Namiot","year":"2023","unstructured":"Namiot ED, Smirnovov\u00e1 D, Sokolov AV, Chubarev VN, Tarasov VV, Schi\u00f6th HB. The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs. Front Pharmacol. 2023;14:1228148.","journal-title":"Front Pharmacol"},{"issue":"1","key":"9909_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12929-023-00976-6","volume":"30","author":"LK Huang","year":"2020","unstructured":"Huang LK, Kuan YC, Lin HW, Hu CJ. Clinical trials of new drugs for Alzheimer disease: a 2020\u20132023 update. J Biomed Sci. 2020;30(1):83.","journal-title":"J Biomed Sci"},{"issue":"7","key":"9909_CR9","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nrd.2016.88","volume":"15","author":"A Bespalov","year":"2016","unstructured":"Bespalov A, Steckler T, Altevogt B, Koustova E, Skolnick P, Deaver D, et al. Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets. Nat Rev Drug Discov. 2016;15(7):516.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"9909_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41231-019-0050-7","volume":"4","author":"AA Seyhan","year":"2019","unstructured":"Seyhan AA. Lost in translation: the valley of death across preclinical and clinical divide\u2013identification of problems and overcoming obstacles. Transl Med Commun. 2019;4(1):1\u201319.","journal-title":"Transl Med Commun"},{"issue":"8","key":"9909_CR11","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1038\/s41591-023-02448-8","volume":"29","author":"AJ Thirunavukarasu","year":"2023","unstructured":"Thirunavukarasu AJ, Ting DSJ, Elangovan K, Gutierrez L, Tan TF, Ting DSW. Large language models in medicine. Nat Med. 2023;29(8):1930\u201340.","journal-title":"Nat Med"},{"issue":"1","key":"9909_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s44163-024-00197-2","volume":"4","author":"SE Doneva","year":"2024","unstructured":"Doneva SE, Qin S, Sick B, Ellendorff T, Goldman J-P, Schneider G, et al. Large language models to process, analyze, and synthesize biomedical texts: a scoping review. Discov Artif Intell. 2024;4(1):107. https:\/\/doi.org\/10.1007\/s44163-024-00197-2.","journal-title":"Discov Artif Intell"},{"issue":"10","key":"9909_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12(10):e1001885.","journal-title":"PLoS Med"},{"issue":"1_suppl","key":"9909_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1740774518755053","volume":"15","author":"P Tenaerts","year":"2018","unstructured":"Tenaerts P, Madre L, Landray M. A decade of the Clinical Trials Transformation Initiative: what have we accomplished? What have we learned? Clin Trials. 2018;15(1_suppl):5\u201312.","journal-title":"Clin Trials"},{"key":"9909_CR15","doi-asserted-by":"crossref","unstructured":"Doneva S, Ellendorff T, Sick B, Goldman JP, Cannon A, Schneider G, et al. NeuroTrialNER: an annotated corpus for neurological diseases and therapies in clinical trial registries. In: Proceedings of the 2024 Conference on Empirical Methods in Natural Language Processing. 2024:18868\u201390.","DOI":"10.18653\/v1\/2024.emnlp-main.1050"},{"key":"9909_CR16","unstructured":"Jurafsky D, Martin J. Vector semantics and embeddings. From speech and language processing: an introduction to natural language processing, computational linguistics, and speech recognition. 2019."},{"key":"9909_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00673","volume":"8","author":"N Perera","year":"2020","unstructured":"Perera N, Dehmer M, Emmert-Streib F. Named entity recognition and relation detection for biomedical information extraction. Front Cell Dev Biol. 2020;8:673.","journal-title":"Front Cell Dev Biol"},{"key":"9909_CR18","doi-asserted-by":"crossref","unstructured":"Kartchner D, Deng J, Lohiya S, Kopparthi T, Bathala P, Domingo-Fern\u00e1ndez D, et al. A comprehensive evaluation of biomedical entity linking models. In: Proceedings of the Conference on Empirical Methods in Natural Language Processing Conference on Empirical Methods in Natural Language Processing. 2023;2023:14462.","DOI":"10.18653\/v1\/2023.emnlp-main.893"},{"key":"9909_CR19","doi-asserted-by":"crossref","unstructured":"Yasunaga M, Leskovec J, Liang P. Linkbert: pretraining language models with document links. 2022. arXiv preprint arXiv:220315827.","DOI":"10.18653\/v1\/2022.acl-long.551"},{"key":"9909_CR20","doi-asserted-by":"crossref","unstructured":"Schwartz AS, Hearst MA. A simple algorithm for identifying abbreviation definitions in biomedical text. In: Biocomputing 2003. World Scientific; 2002. p. 451\u201362.","DOI":"10.1142\/9789812776303_0042"},{"issue":"3","key":"9909_CR21","first-page":"527","volume":"13","author":"\u00d6 Sevgili","year":"2022","unstructured":"Sevgili \u00d6, Shelmanov A, Arkhipov M, Panchenko A, Biemann C. Neural entity linking: a survey of models based on deep learning. Semant Web. 2022;13(3):527\u201370.","journal-title":"Semant Web"},{"issue":"6","key":"9909_CR22","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1093\/bib\/bbaa054","volume":"21","author":"MS Huang","year":"2020","unstructured":"Huang MS, Lai PT, Lin PY, You YT, Tsai RTH, Hsu WL. Biomedical named entity recognition and linking datasets: survey and our recent development. Brief Bioinform. 2020;21(6):2219\u201338.","journal-title":"Brief Bioinform"},{"issue":"9","key":"9909_CR23","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/jamia\/ocab084","volume":"28","author":"E Chang","year":"2013","unstructured":"Chang E, Mostafa J. The use of SNOMED CT, 2013-2020: a literature review. J Am Med Inform Assoc. 2013;28(9):2017\u201326.","journal-title":"J Am Med Inform Assoc"},{"key":"9909_CR24","doi-asserted-by":"crossref","unstructured":"Liu F, Shareghi E, Meng Z, Basaldella M, Collier N. Self-alignment pretraining for biomedical entity representations. 2020. arXiv preprint arXiv:201011784.","DOI":"10.18653\/v1\/2021.naacl-main.334"},{"issue":"1","key":"9909_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1145\/3458754","volume":"3","author":"Y Gu","year":"2021","unstructured":"Gu Y, Tinn R, Cheng H, Lucas M, Usuyama N, Liu X, et al. Domain-specific language model pretraining for biomedical natural language processing. ACM Trans Comput Healthc. 2021;3(1):1\u201323.","journal-title":"ACM Trans Comput Healthc"},{"key":"9909_CR26","unstructured":"Van der Maaten L, Hinton G. Visualizing data using t-SNE. J Mach Learn Res. 2008;9:11."},{"key":"9909_CR27","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-M\u00e1rquez R, Schmidt L, Schmidt BM, Berens P, Kobak D. The landscape of biomedical research. Patterns. 2024;5:6.","DOI":"10.1016\/j.patter.2024.100968"},{"key":"9909_CR28","doi-asserted-by":"crossref","unstructured":"Zwierzyna M, Davies M, Hingorani AD, Hunter J. Clinical trial design and dissemination: comprehensive analysis of clinicaltrials. gov and PubMed data since 2005. Bmj. 2018;361:k2130.","DOI":"10.1136\/bmj.k2130"},{"key":"9909_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neuropharm.2016.03.021","volume":"120","author":"VK Gribkoff","year":"2017","unstructured":"Gribkoff VK, Kaczmarek LK. The need for new approaches in CNS drug discovery: why drugs have failed, and what can be done to improve outcomes. Neuropharmacology. 2017;120:11\u20139.","journal-title":"Neuropharmacology"},{"key":"9909_CR30","first-page":"1142","volume-title":"New statistics on the cost of new drug development and the trouble with CNS drugs","author":"CW Lindsley","year":"2014","unstructured":"Lindsley CW. New statistics on the cost of new drug development and the trouble with CNS drugs, vol. 5. ACS Publications; 2014. p. 1142."},{"issue":"2","key":"9909_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41591-022-02197-0","volume":"29","author":"KW Scangos","year":"2023","unstructured":"Scangos KW, State MW, Miller AH, Baker JT, Williams LM. New and emerging approaches to treat psychiatric disorders. Nat Med. 2023;29(2):317\u201333.","journal-title":"Nat Med"},{"key":"9909_CR32","doi-asserted-by":"crossref","unstructured":"Sedgwick P. External and internal validity in clinical trials. Bmj. 2012;344:e1004.","DOI":"10.1136\/bmj.e1004"},{"issue":"10221","key":"9909_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0140-6736(19)33220-9","volume":"395","author":"NJ DeVito","year":"2020","unstructured":"DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet. 2020;395(10221):361\u20139.","journal-title":"Lancet"},{"issue":"7","key":"9909_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068409","volume":"8","author":"V Huser","year":"2013","unstructured":"Huser V, Cimino JJ. Linking ClinicalTrials.gov and PubMed to track results of interventional human clinical trials. PLoS ONE. 2013;8(7):e68409.","journal-title":"PLoS ONE"},{"issue":"10289","key":"9909_CR35","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","volume":"397","author":"SP Cohen","year":"2021","unstructured":"Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet (London, England). 2021;397(10289):2082\u201397.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"9909_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1152\/physrev.00045.2019","volume":"101","author":"NB Finnerup","year":"2021","unstructured":"Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: from mechanisms to treatment. Physiol Rev. 2021;101(1):259\u2013301.","journal-title":"Physiol Rev"},{"issue":"1","key":"9909_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/bja\/aet123","volume":"111","author":"O Van Hecke","year":"2013","unstructured":"Van Hecke O, Torrance N, Smith B. Chronic pain epidemiology and its clinical relevance. Br J Anaesth. 2013;111(1):13\u20138.","journal-title":"Br J Anaesth"},{"issue":"12","key":"9909_CR38","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.jpain.2014.09.004","volume":"15","author":"RW Gereau IV","year":"2014","unstructured":"Gereau RW IV, Sluka KA, Maixner W, Savage SR, Price TJ, Murinson BB, et al. A pain research agenda for the 21st century. J Pain. 2014;15(12):1203\u201314.","journal-title":"J Pain"},{"issue":"12","key":"9909_CR39","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jamaneurol.2022.3543","volume":"79","author":"JJ Manly","year":"2016","unstructured":"Manly JJ, Jones RN, Langa KM, Ryan LH, Levine DA, McCammon R, et al. Estimating the prevalence of dementia and mild cognitive impairment in the US: the 2016 health and retirement study harmonized cognitive assessment protocol project. JAMA Neurol. 2016;79(12):1242\u20139.","journal-title":"JAMA Neurol"},{"issue":"5","key":"9909_CR40","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2174\/138161210790361461","volume":"16","author":"RB Mailman","year":"2010","unstructured":"Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity. Curr Pharm Des. 2010;16(5):488\u2013501.","journal-title":"Curr Pharm Des"},{"issue":"9","key":"9909_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094467","volume":"22","author":"FV Gomes","year":"2021","unstructured":"Gomes FV, Grace AA. Beyond dopamine receptor antagonism: new targets for schizophrenia treatment and prevention. Int J Mol Sci. 2021;22(9):4467.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"9909_CR42","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S2215-0366(21)00243-1","volume":"8","author":"I Bighelli","year":"2021","unstructured":"Bighelli I, Rodolico A, Garc\u00eda-Mieres H, Pitschel-Walz G, Hansen W-P, Schneider-Thoma J, et al. Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry. 2021;8(11):969\u201380.","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"9909_CR43","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1177\/0269881114565806","volume":"29","author":"J Dunlop","year":"2015","unstructured":"Dunlop J, Brandon NJ. Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations. J Psychopharmacol. 2015;29(2):230\u20138.","journal-title":"J Psychopharmacol"},{"issue":"8","key":"9909_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081689","volume":"18","author":"AC Yang","year":"2017","unstructured":"Yang AC, Tsai S-J. New targets for schizophrenia treatment beyond the dopamine hypothesis. Int J Mol Sci. 2017;18(8):1689.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"9909_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01904-2","volume":"12","author":"DL Spark","year":"2022","unstructured":"Spark DL, Fornito A, Langmead CJ, Stewart GD. Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics. Transl Psychiatry. 2022;12(1):147.","journal-title":"Transl Psychiatry"},{"issue":"2","key":"9909_CR46","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.genhosppsych.2015.01.003","volume":"37","author":"EE Lee","year":"2015","unstructured":"Lee EE, Della Selva MP, Liu A, Himelhoch S. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry. 2015;37(2):178\u201384.","journal-title":"Gen Hosp Psychiatry"},{"key":"9909_CR47","doi-asserted-by":"crossref","unstructured":"Corriger A, Pickering G. Ketamine and depression: a narrative review. Drug design, development and therapy. 2019:3051-67.","DOI":"10.2147\/DDDT.S221437"},{"key":"9909_CR48","doi-asserted-by":"crossref","unstructured":"Han Y, Chen J, Zou D, Zheng P, Li Q, Wang H, et al. Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatric disease and treatment. 2016:2859-67.","DOI":"10.2147\/NDT.S117146"},{"issue":"9","key":"9909_CR49","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1056\/NEJMsa1012065","volume":"364","author":"DA Zarin","year":"2011","unstructured":"Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database\u2014update and key issues. N Engl J Med. 2011;364(9):852\u201360.","journal-title":"N Engl J Med"},{"key":"9909_CR50","unstructured":"Organization WH. International standards for clinical trial registries: the registration of all interventional trials is a scientific, ethical and moral responsibility. In: International standards for clinical trial registries: the registration of all interventional trials is a scientific, ethical and moral responsibility. 2018."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09909-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09909-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09909-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:20:48Z","timestamp":1792711248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09909-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9909"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09909-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"25 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DSR has received research funding from Abata and Sanofi. BVI received a speaker fee from CSL Behring. The other authors have nothing to declare.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"622"}}